KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced new interim results from its KONFIDENT-KID clinical trial ...

KalVista Pharmaceuticals recently reported interim results from its KONFIDENT-KID trial, showing that oral EKTERLY (sebetralstat) provided rapid, well-tolerated on-demand treatment for 172 hereditary ...

Enrollment completed in CHAPTER-3, a pivotal study of deucrictibant XR for prophylactic treatment of HAE attacks; topline data anticipated in ...

An update from Pharvaris ( (PHVS) ) is now available.

Data include a concurrent assessment of results collected from PGI and AMRA instruments, insights into clinically meaningful changes in HAE attack symptoms, and support for hierarchical ranking of ...

Long-term use of donidalorsen helps prevent swelling attacks in patients with hereditary angioedema (HAE), according to the results of a 4-year open-label extension (OLE) study (NCT04307381) published ...

PHILADELPHIA — The investigational drug navenibart reduced attacks of hereditary angioedema by an average 91% over 1 year with only twice-yearly dosing and no serious adverse effects or safety signals ...

A new report suggests patients with obesity and chronic spontaneous urticaria (CSU) tend to be older when diagnosed with the latter condition, and are also less likely to respond to omalizumab (Xolair ...

KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that five abstracts, including one late-breaking submission, ...

RAPIDe-3 met the primary and all 11 secondary efficacy endpoints with high statistical significance with deucrictibant achieving onset of symptom relief in 1.28 hours and complete symptom resolution ...